LDX Lumos Diagnostics Holdings Limited
Healthcare · Medical Devices
· website
$0.10
52wk 0.08 – 0.33
Overall
40.6
Value
80.9
Growth
47.8
Health
50.3
Quality
0.0
Momentum
5.1
Dividend
—
Price
About Lumos Diagnostics Holdings Limited
Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | -9.1% |
| 1 month | 3.1% |
| 3 months | -9.1% |
| 6 months | -52.4% |
| 1 year | -33.3% |
| 3 years | 0.0% |
Risk
| Volatility (1y ann.) | 107.2% |
| Beta vs ASX 200 | 1.53 |
| Sharpe (1y) | 0.10 |
| VaR 95% (1-day) | -9.1% |
| Max drawdown (1y) | -75.0% |
| Off 1-year high | -68.7% |
Technicals
| RSI(14) | 50 |
| vs 50DMA | -7.0% |
| vs 200DMA | -42.1% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
80.9
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
70
Price / Sales
29
Growth
47.8
Revenue growth (1y)
44
Revenue CAGR (3y)
51
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
50.3
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
42
Debt / Equity
97
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
5.1
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
15
Position in 52-week range
9
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$97.17M
P/E (trailing)
—
P/E (forward)
-7.15
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.54
EV / EBITDA
-6.27
Price / Book
2.99
ROE
-34.1%
Operating margin
-107.7%
Net margin
-37.5%
Total cash
$15.43M
Total debt
$5.94M
Current ratio
1.52
Debt / Equity
0.26
Free cash flow
$-1.84M
Avg volume
1.71M
Latest annual results
(FY ending 30 Jun 2026)
- Revenue$13.19M
- Gross profit$7.93M
- Operating income-$14.07M
- Net income-$4.95M
- Diluted EPS-0.01
- Free cash flow-$1.52M
- Net debt-$9.49M